Page 151 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

84. Kohler BA, Ward E, McCarthy BJ, et al. 94. Merrill RM, Dearden KA. How
Annual report to the nation on the status of
cancer, 1975-2007, featuring tumors of the
brain and other nervous system. J Natl
Cancer Inst 2011;103:714-736.
85. Schwartz KL, Severson RK, Gurney JG, et 95.
al. Trends in the stage specific incidence of
prostate carcinoma in the Detroit
metropolitan area, 1973-1994. Cancer
1996;78:1260-1266.
86. Barnholtz-Sloan JS, Severson RK, 96.
Vaishampayan U, et al. Survival analysis of
distant prostate cancer by decade (1973-
1997) in the Detroit Metropolitan
Surveillance, Epidemiology and End Results
(SEER) Program registry: has outcome
improved? (United States). Cancer Causes 97.
Control 2003;14:681-685.
87. Warren JL, Yabroff KR, Meekins A, et al.
Evaluation of trends in the cost of initial
cancer treatment. J Natl Cancer Inst. 98.
2008;100:888-897.
88. Gross CP, Smith BD, Wolf E, et al. Racial
disparities in cancer therapy: did the gap
narrow between 1992 and 2002? Cancer 99.
2008;112:900-908.
89. Welch HG, Fisher ES, Gottlieb DJ, et al.
Detection of prostate cancer via biopsy in
the Medicare-SEER population during the 100.
PSA era. J Natl Cancer Inst 2007;99:1395-
1400.
90. Cooperberg MR, Cowan J, Broering JM, et
al. High-risk prostate cancer in the United
States, 1990-2007. World J Urol
2008;26:211-218. 101.
91. Mettlin CJ, Murphy GP, McDonald CJ, et
al. The National Cancer Data base Report on 102.
increased use of brachytherapy for the
treatment of patients with prostate
carcinoma in the U.S. Cancer 1999;86:1877-
1882.
103.
92. White A, Coker AL, Du XL, et al.
Racial/ethnic disparities in survival among
men diagnosed with prostate cancer in
Texas. Cancer 2011;117:1080-1088.
104.
93. Frey CM, McMillen MM, Cowan CD, et al.
Representativeness of the surveillance,
epidemiology, and end results program data:
recent trends in cancer mortality rates. J Natl
Cancer Inst 1992;84:872-877.
97
representative are the surveillance,
epidemiology, and end results (SEER)
program cancer data of the United States?
Cancer Causes Control 2004;15:1027-1034.
Warren JL, Klabunde CN, Schrag D, et al.
Overview of the SEER-Medicare data:
content, research applications, and
generalizability to the United States elderly
population. Med Care 2002;40:IV-18.
Etzioni R, Penson DF, Legler JM, et al.
Overdiagnosis due to prostate-specific
antigen screening: lessons from U.S.
prostate cancer incidence trends. J Natl
Cancer Inst 2002;94:981-990.
Albertsen PC, Hanley JA, Barrows GH, et
al. Prostate cancer and the Will Rogers
phenomenon. J Natl Cancer Inst
2005;97:1248-1253.
Feinstein AR, Sosin DM, Wells CK. The
Will Rogers phenomenon. Stage migration
and new diagnostic techniques as a source of
misleading statistics for survival in cancer.
N Engl J Med 1985;312:1604-1608.
Gofrit ON, Zorn KC, Steinberg GD, et al.
The Will Rogers phenomenon in urological
oncology. J Urol 2008;179:28-33.
Feuer EJ, Merrill RM, Hankey BF. Cancer
surveillance series: interpreting trends in
prostate cancer--part II: Cause of death
misclassification and the recent rise and fall
in prostate cancer mortality. J Natl Cancer
Inst 1999;91:1025-1032.
Tsodikov A, Szabo A, Wegelin J. A
population model of prostate cancer
incidence. Stat Med 2006;25:2846-2866.
Etzioni R, Tsodikov A, Mariotto A, et al.
Quantifying the role of PSA screening in the
US prostate cancer mortality decline. Cancer
Causes Control 2008;19:175-181.
Telesca D, Etzioni R, Gulati R. Estimating
lead time and overdiagnosis associated with
PSA screening from prostate cancer
incidence trends. Biometrics 2008;64:10-19.
Draisma G, Postma R, Schroder FH, et al.
Gleason score, age and screening: modeling
dedifferentiation in prostate cancer. Int J
Cancer 2006;119:2366-2371.